Validation of a modified-composite autonomic symptom score (COMPASS-31) as an outcome measure for persistent autonomic symptoms post-concussion: an observational pilot study.
| Autor: | Hammerle MH; Brooke Army Medical Center Brain Injury Rehabilitation Service, JBSA Fort Sam Houston, San Antonio, Texas, USA., Lu LH; Traumatic Brain Injury Center of Excellence, Silver Spring, Maryland, USA.; Brooke Army Medical Center, JBSA, Texas, USA.; General Dynamics Information Technology, Falls Church, Virginia, USA., Thomas LC; Neck Pain and Whiplash Research Unit, School of Health and Rehabilitation Services, University of Queensland, Brisbane, Queensland, Australia., Swan AA; Department of Psychology, South Texas Veterans Health Care System & The University of Texas at San Antonio, San Antonio, Texas, USA., Treleaven JM; Neck Pain and Whiplash Research Unit, School of Health and Rehabilitation Services, University of Queensland, Brisbane, Queensland, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Brain injury [Brain Inj] 2024 Sep 18; Vol. 38 (11), pp. 896-901. Date of Electronic Publication: 2024 May 20. |
| DOI: | 10.1080/02699052.2024.2355588 |
| Abstrakt: | Objective: Persistent symptoms post-mild traumatic brain injury (mTBI) includes autonomic dysregulation (AD). The composite autonomic symptoms score, (COMPASS-31), was developed to quantify AD symptom severity in the last year, which limits clinical utility. The primary aim was to determine validity of a modified-COMPASS-31 measuring symptoms in the last month compared to the original, secondarily to compare both original and modified versions to the Neurobehavioral Symptom Inventory (NSI), and tertiarily to detect change post-treatment of the modified-COMPASS-31 compared to NSI and headache intensity (HI). Participants: Thirty-three military personnel with persistent headache post-mTBI. Main Outcome Measures: Total and domain scores for COMPASS-31 (original vs. modified) NSI and HI at baseline. Change in modified-COMPASS-31. NSI, and HI. Results: Baseline COMPASS-31 versions were comparable and highly correlated ( r = 0.72, p < 0.001), they were moderately correlated at best to the NSI ( r < 0.6), which may suggest differences in measurement metrics. The mean change in modified-COMPASS-31 scores (15.4/100, effect size 0.8) was mild to moderately correlated to the change in HI ( r = 0.39) score, but not to NSI ( r = 0.28). Conclusion: The modified-COMPASS-31 appears to be valid, can measure change of AD symptom severity, and is recommended as an outcome measure. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|